Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cash for quitting: new study tests rewards and meds to help HIV patients stop smoking

NCT ID NCT04490057

Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested different ways to help people living with HIV quit smoking. Participants received nicotine replacement therapy (like patches or gum), the medications varenicline or bupropion, and financial rewards for staying smoke-free. The goal was to see if these approaches could reduce the number of cigarettes smoked per day. The study enrolled 323 adults with HIV who smoked at least 5 cigarettes daily.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler, varenicline, bupropion
What this could lead to
If successful, this could point toward effective, personalized ways to help people with HIV quit smoking, reducing their risk of smoking-related diseases.
What could go wrong
This is a completed Phase 4 study, but results may not apply to all smokers with HIV. Self-reported smoking reduction may be less reliable than objective measures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

323 people

The number who actually took part.

Started

Jul 2020

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV positive; * \>= 18 years old * Receiving HIV care at Yale-New Haven Hospital, Bridgeport Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic; * Have smoked \>= 100 cigarettes in lifetime; * Currently smokes some days or every day; * Smokes, on average, \>= 5 cigarettes per day; * Able to provide written informed consent. Exclusion Criteria: * Using only non-cigarette nicotine products (i.e., e-cigs, Juul, etc.); * Currently using NRT, VAR, or bupropion (defined as use in the prior 7 days); * Self-report or urine testing confirming pregnancy, nursing, or trying to conceive; * Life-threatening or unstable medical, surgical, or psychiatric condition; * Inability to provide at least one collateral contact (family member or friend); * Living out of state; * Unable to read or understand English (except at Mount Sinai site).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease nicotine dependence Tobacco Use Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tobacco use cessation

Contacts and locations

Locations

  • Bridgeport Hospital Infectious Disease Clinic

    Bridgeport, Connecticut, 06110, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • SUNY Downstate STAR Clinic

    Brooklyn, New York, 11203, United States

  • Yale University School of Medicine

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.